Hyalprotect Injection (Sodium Hyaluronate) (Pre-filled)

Adult administration

1. Cataract surgery and intraocular lens implantation: Inject the required amount slowly into the anterior chamber before or after lens extraction using a needle or cannula. Administer before intraocular and extraocular cataract surgery. 2. Corneal transplantation surgery: After removing the corneal graft, fill the anterior chamber with this drug until the corneal surface and stroma match, place the donor graft on top, and suture it. 3. Glaucoma filtration surgery: Inject this drug through corneal puncture to supplement and maintain anterior chamber volume during trabeculectomy.

This drug contains sodium hyaluronate as the main ingredient and is primarily used after ophthalmic surgeries. This drug should not be administered to patients who have had allergic reactions to this ingredient or protein-based medications. Side effects may occur in the eyes, including a temporary increase in intraocular pressure or inflammation within the eye. Additionally, corneal swelling or clouding may occur, and there is a risk of bleeding or abnormalities in the iris region. Symptoms such as eye pain, itching, or vision deterioration may arise, so caution is necessary. When using this drug after surgery, it is essential to carefully monitor the intraocular pressure. If it increases, appropriate treatment must be administered. After surgery, it is advisable to clean or aspirate this drug as thoroughly as possible. If ultrasonic emulsification and aspiration are performed before surgery, care must be taken to ensure that the medication is evenly distributed within the eye through aspiration and perfusion. When cleaning surgical instruments, solutions containing quaternary ammonium compounds such as benzalkonium chloride should not be used. This drug is derived from avian cells, so potential immune reactions or other risks should be acknowledged. This drug should not be used in conjunction with hyaluronidase. For ophthalmic use only and must never be injected intravascularly. Before use, the refrigerated drug should be brought to room temperature by leaving it for about 30 minutes, and any remaining medication after opening should be discarded after one use. When mixing the drug with air, care must be taken to prevent air from entering under the iris, and administration should be done slowly and carefully. When injecting into the anterior chamber, caution must be taken to avoid excessive injection, as overdosing can lead to an increase in intraocular pressure. This drug should be kept out of the reach of children, stored in a cool place away from direct sunlight and moisture.

Mild side effects

Increased ocular pressure, inflammatory reactions, corneal edema, corneal clouding, anterior bleeding, iris neovascularization, iris posterior ulcer, conjunctival adhesion failure, mydriasis, lens clouding, pain, itching, blurred vision, corneal targeted dysfunction, clouding on the surface of the intraocular lens, corneal calcification.

This drug should be stored in a sealed container to prevent contact with air, and the temperature must be kept between 2°C and 8°C in a cool place. Care should be taken to avoid direct sunlight and freezing.

Appearance

A colorless, transparent, and viscous liquid contained in a glass vial sealed with rubber stoppers on both ends (part of the pre-filled syringe system).

Package unit

0.85mL/vial, 1.5mL/vial